Zydus Lifesciences to acquire majority stake in Amplitude Surgical

Zydus Lifesciences (BSE: ZYDUSLIFE) is set to acquire a majority stake in Amplitude Surgical SA, a French company specializing in lower limb orthopedic surgical technologies. This strategic move follows Amplitude obtaining a positive opinion from its Social and Economic Committee, completing the mandatory information and consultation process in France. Zydus has signed a share purchase agreement to acquire 75.4% of Amplitude Surgical's share capital from PAI Partners, Olivier Jallabert, and other managers at a price of EUR 6.25 per share. Combined with existing agreements with minority shareholders, Zydus will control 85.6% of Amplitude Surgical. The Block Acquisition, expected to close in Q3 2025, remains subject to customary closing conditions, including regulatory approval from the French Minister of Economy and the re-investment by Amplitude CEO Olivier Jallabert. Zydus subsidiary, Zydus MedTech (France) SAS, will complete the acquisition of equity shares. Following the Block Acquisition, Zydus will file a mandatory simplified tender offer with the Autorité des Marchés Financiers ("AMF") for the remaining shares. The company intends to implement a squeeze-out procedure to acquire more than 90% share capital and voting rights.